Borchers H, Meyers F J, Gumerlock P H, Stewart S L, deVere White R W
Department of Urology, University of California, Davis, Sacramento 95817, USA.
J Urol. 1996 Jun;155(6):2080-4.
To investigate whether NM23 (nm23-H1, nm23-H2), a metastasis suppressor gene family, is a molecular marker indicative of metastatic potential of localized carcinoma of the prostate (CaP). Previously, we found decreased nm23-H2 expression correlated with an increase in stage, and here we have expanded the cohort.
Eighty prostate tissue samples from patients with CaP and benign prostatic hyperplasia (BPH) were examined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for NM23 gene expression. Samples were grouped according to stage, grade and whether the patient received combined androgen blockade (CAB) prior to surgery.
We could not confirm our initial results of an inverse correlation of nm23-H2 expression levels with grade. However, two significant results were found after CAB: 1) nm23-H1 expression was reduced (p = 0.003), and 2) nm23-H2 expression across stage and grade was uniformly higher (p = 0.003) than in untreated samples.
NM23 appears not to be a useful molecular marker of metastatic potential in CaP. The altered gene expression after CAB may relate to a cancer cell subpopulation insensitive to apoptosis induced by hormone withdrawal.
研究转移抑制基因家族NM23（nm23-H1、nm23-H2）是否为局限性前列腺癌（CaP）转移潜能的分子标志物。此前，我们发现nm23-H2表达降低与分期增加相关，在此我们扩大了队列研究。
采用定量逆转录聚合酶链反应（RT-PCR）检测80例CaP患者及良性前列腺增生（BPH）患者的前列腺组织样本中NM23基因的表达。样本根据分期、分级以及患者术前是否接受联合雄激素阻断（CAB）进行分组。
我们未能证实nm23-H2表达水平与分级呈负相关的初步结果。然而，在CAB后发现了两个显著结果：1）nm23-H1表达降低（p = 0.003），2）各分期和分级的nm23-H2表达均高于未治疗样本（p = 0.003）。
NM23似乎不是CaP转移潜能的有用分子标志物。CAB后基因表达的改变可能与对激素撤退诱导的凋亡不敏感的癌细胞亚群有关。
